Acquired Hemophilia Medical Services in China

Acquired Hemophilia (AH) is a rare, life-threatening autoimmune bleeding disorder characterized by the spontaneous development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII) in individuals with no prior personal or family history of hemophilia. Unlike congenital hemophilia, AH occurs de novo—typically in older adults—and results in impaired thrombin generation and defective fibrin clot formation. Pathogenesis centers on loss of immune tolerance: autoreactive B cells produce immunoglobulin G (IgG) antibodies that neutralize FVIII activity or accelerate its clearance, leading to markedly prolonged activated partial thromboplastin time (aPTT), undetectable or low FVIII activity (<1–5% of normal), and presence of an FVIII inhibitor confirmed by Bethesda or Nijmegen-Bethesda assay. Approximately 50% of cases are idiopathic; the remainder are associated with underlying conditions including autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus), malignancies (especially lymphoproliferative disorders and solid tumors in elderly patients), pregnancy (postpartum onset), and exposure to certain medications (e.g., interferon-alpha, penicillamine). Epidemiologically, AH has an incidence of 1–1.5 cases per million person-years, with median age at diagnosis of 70–80 years and no significant sex predilection—though slightly higher incidence is reported in women, possibly linked to postpartum cases. Risk factors include advanced age (>65 years), female sex (particularly in postpartum period), autoimmune comorbidity, active malignancy, and chronic inflammatory states. Clinically, patients present with sudden, severe, and often spontaneous bleeding—including extensive subcutaneous hematomas, muscle bleeds, gastrointestinal or urogenital hemorrhage, retroperitoneal bleeding, and, rarely, intracranial hemorrhage. Unlike congenital hemophilia, joint bleeds (hemarthroses) are uncommon. Delayed diagnosis is frequent due to nonspecific symptoms and lack of awareness, contributing to high early mortality (up to 20% within weeks), primarily from uncontrolled hemorrhage or complications of immunosuppressive therapy. Quality of life is profoundly impacted: patients experience acute pain, functional disability, anxiety about recurrent bleeding, treatment-related side effects (e.g., infections, hyperglycemia, hypertension from corticosteroids), hospitalization burden, and psychosocial distress. Long-term survivors may face chronic anemia, organ damage from recurrent bleeds, and persistent fatigue. Early recognition, rapid hemostatic control using bypassing agents (e.g., recombinant activated factor VII or activated prothrombin complex concentrate), and prompt initiation of immunosuppression (prednisone ± cyclophosphamide or rituximab) are critical to survival and functional recovery.

Acquired hemophilia A (AHA) is a rare, life-threatening autoimmune bleeding disorder characterized by the development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII). Unlike congenital hemophilia, AHA occurs de novo in individuals with no prior personal or family history of bleeding diathesis—typically in older adults (median age 60–80 years), though it may affect any age group, including postpartum women. The condition carries significant morbidity and mortality, primarily due to uncontrolled spontaneous or trauma-induced hemorrhage (e.g., muscle hematomas, gastrointestinal, retroperitoneal, or intracranial bleeding), with reported mortality rates of 15–25% within the first year. Management requires a multidisciplinary approach coordinated by hematologists, immunologists, transfusion medicine specialists, and critical care teams.

Conservative treatment forms the cornerstone of initial management and focuses on two parallel objectives: (1) immediate hemostatic control and (2) eradication of the pathogenic autoantibody. Hemostatic support must be initiated promptly upon suspicion—even before confirmatory laboratory testing—to prevent irreversible organ damage or exsanguination. Patients should be admitted to a specialized hematology unit with 24/7 access to coagulation laboratories, point-of-care viscoelastic testing (e.g., thromboelastography), and on-site blood bank services. Bed rest, strict avoidance of intramuscular injections, invasive procedures (unless lifesaving and meticulously planned), and antiplatelet/anticoagulant agents is mandatory. Serial clinical assessment—including neurological, abdominal, and musculoskeletal examinations—is essential to detect occult bleeding. Monitoring includes serial FVIII activity assays, inhibitor titer (Bethesda assay), global coagulation tests (aPTT, fibrinogen, D-dimer), and complete blood count. In asymptomatic patients with low-titer inhibitors (<5 BU/mL) and no active bleeding, observation alone may be considered—but only after thorough risk stratification and shared decision-making.

Pharmacologic therapy is stratified into hemostatic agents and immunosuppressive regimens. For acute bleeding, bypassing agents are first-line: recombinant activated factor VII (rFVIIa; 90 µg/kg IV bolus every 2–3 hours until hemostasis) or activated prothrombin complex concentrate (aPCC; FEIBA®, 50–100 IU/kg IV, repeated as needed, with cumulative daily dose capped at 200 IU/kg to mitigate thrombotic risk). rFVIIa is preferred in patients with high inhibitor titers (>10 BU/mL), renal impairment, or thrombotic history; aPCC may be favored when cost or availability is limiting—but requires careful monitoring for disseminated intravascular coagulation or arterial thrombosis. Human plasma-derived FVIII is ineffective and contraindicated due to neutralization by inhibitors. Desmopressin has no role in AHA. Immunosuppression aims to eliminate inhibitor-producing plasma cells. First-line therapy is corticosteroids (prednisone 1 mg/kg/day orally, tapered over 4–6 weeks) combined with cyclophosphamide (1.5–2 mg/kg/day orally for 4–6 weeks). This regimen achieves complete remission (CR; inhibitor undetectable + FVIII >50 IU/dL) in ~70–80% of patients within 4–8 weeks. For steroid-intolerant or refractory cases, rituximab (375 mg/m² IV weekly × 4 doses) is recommended—particularly in elderly patients or those with comorbidities precluding alkylating agents. Emerging options include calcineurin inhibitors (tacrolimus), proteasome inhibitors (bortezomib), and newer B-cell modulators (e.g., obinutuzumab), though evidence remains limited to case series and small trials. All immunosuppressed patients require Pneumocystis jirovecii prophylaxis (e.g., trimethoprim-sulfamethoxazole), vaccination updates (non-live vaccines only), and vigilant infection surveillance.

Surgical intervention is rarely indicated and reserved exclusively for life- or limb-threatening hemorrhage unresponsive to medical hemostasis—such as expanding retroperitoneal hematoma causing compartment syndrome or airway compromise from neck hematoma. Surgery must be performed in centers with integrated hematology-thrombosis support, using intraoperative rFVIIa or aPCC infusions guided by real-time coagulation monitoring. Elective surgery is contraindicated during active disease; if unavoidable (e.g., urgent cancer resection), it must be preceded by ≥2 weeks of effective immunosuppression and confirmed inhibitor titer reduction (>50% decline and <5 BU/mL). Preoperative FVIII recovery testing is not predictive and should not delay therapy.

Treatment advantages in China include rapid diagnostic capacity through nationally accredited hemophilia reference laboratories (e.g., at Peking Union Medical College Hospital and Ruijin Hospital), standardized inhibitor assays aligned with ISTH guidelines, and centralized pharmacovigilance for bypassing agents. China’s National Reimbursement Drug List (NRDL) now covers rFVIIa and rituximab for AHA, significantly improving accessibility. Multicenter registries (e.g., the Chinese Acquired Hemophilia Registry, CAHR) facilitate real-world outcome tracking and protocol refinement. Additionally, China’s robust telehematology infrastructure enables timely remote consultation for rural referrals, reducing time-to-treatment. Traditional Chinese Medicine (TCM) adjuncts are sometimes used under hematologist supervision for supportive symptom management (e.g., astragalus for immune modulation), but TCM is never substituted for evidence-based immunosuppression or hemostatic therapy.

Recovery advice emphasizes long-term vigilance. Patients achieving CR require monthly FVIII activity and inhibitor titer monitoring for at least 6 months, then quarterly for 1 year, given the 10–15% relapse risk—most commonly within 6 months of immunosuppression cessation. Education on early bleeding recognition (e.g., prolonged oozing, new bruising, hematuria) and emergency action plans—including carrying an AHA identification card with treatment protocol—is critical. Physical rehabilitation should be gradual and supervised by physiotherapists experienced in coagulopathies; aquatic therapy may be introduced once FVIII >50 IU/dL and inhibitor-negative. Psychosocial support is integral: depression and anxiety prevalence exceeds 40% in AHA survivors, warranting routine screening and referral to mental health services. Vaccination against hepatitis A/B, influenza, and pneumococcus is strongly encouraged. Pregnancy counseling is essential for women of childbearing potential, as postpartum AHA recurrence risk is elevated. Finally, patients should avoid NSAIDs indefinitely and consult hematologists before any new medication, including herbal supplements, due to unpredictable interactions with immunosuppressants or coagulation pathways.